<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00149396</url>
  </required_header>
  <id_info>
    <org_study_id>CT1030</org_study_id>
    <nct_id>NCT00149396</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver</brief_title>
  <official_title>A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of
      the study to determine and evaluate the safety and tolerability of repeated treatments with a
      genetically engineered herpes simplex virus NV1020 administered locoregionally to the liver.

      Stage 2 is to evaluate the dose found in Stage 1 to be &quot;optimally tolerated&quot;. Stage 2 is to
      assess the efficacy of the optimally tolerated dose of NV1020 by itself and in combination
      with second-line chemotherapy.

      Assignment to Stage 1 or Stage 2 of the study is determined by when the patient enters the
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the effects of repeated treatments with NV1020, prior to
      second-line chemotherapy, and to determine an appropriate dose level of NV1020 in a multiple
      dose regimen for later Phase II studies.

      Sequential, open-label cohort dose escalation of NV1020 (stage 1) followed by an expansion of
      one selected dose cohort (stage 2).

      Study results will be reviewed periodically by an independent DSMB who will approve each
      cohort dose escalation.

      During the dose escalation stage, 3 cohorts of patients (3 in each) will be treated with 4
      fixed doses of NV1020, with the dose level increasing for successive cohorts. A patient will
      be observed for a minimum of 7 days after the first NV1020 infusion before the next patient
      in the same cohort is given NV1020. The first patient in the next higher dose cohort will
      receive NV1020 no earlier than 14 days after the last patient in the prior cohort has
      finished NV1020 infusions. One additional cohort (half log higher increment) may be approved
      by the DSMB, if considered necessary to define MTD. Dose-limiting toxicity will be determined
      using NCI CTC criteria and a suitable dose level for later evaluation will be selected.

      In the second stage of the study, the dose cohort considered to show the best therapeutic
      index will be expanded by the addition of 18 further patients. For all patients in this
      study, investigational treatment with NV1020 will be followed by a minimum of two cycles of
      second-line therapy using anti-neoplastic drugs approved by the FDA for colorectal cancer and
      selected by the investigator.

      All patients will be followed up periodically until death. Permission for autopsy will be
      sought.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events and Dose Limiting Adverse Events</measure>
    <time_frame>From start of treatment through 12 months after completion of treatment</time_frame>
    <description>Incidence of adverse events for all patients (N=32); Overall incidence â‰¥20%; Adverse events listed by Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NV1020 Pharmacokinetics - Presence of NV1020 in Body Fluids/Skin</measure>
    <time_frame>Daily for 2 weeks after the first and last NV1020 infusions</time_frame>
    <description>Number of patients with NV1020 detected in saliva, skin, and/or mucosal surfaces; Analysis by polymerase chain reaction (PCR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Safety - Hematology</measure>
    <time_frame>Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment</time_frame>
    <description>Number of patients with clinically significant hematology laboratory abnormalities by NV1020 dose cohort (Post baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Safety - Chemistry</measure>
    <time_frame>Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment</time_frame>
    <description>Number of patients with post-baseline clinically significant laboratory chemistry abnormalities by NV1020 dose cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Safety - Coagulation</measure>
    <time_frame>Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment</time_frame>
    <description>Number of patients with post-baseline clinically significant laboratory coagulation abnormalities by NV1020 dose cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Serum Carcinoembryonic Antigen (CEA) After Administration of NV1020 and 2 Cycles of Chemotherapy</measure>
    <time_frame>Screening (baseline), Chemo visit 1, Chemo visit 2, Follow-up Visit 1 (1 week after end of treatment), Follow-up Visit 2 (+6M), Follow-up Visit 3 (+9M), Follow-up Visit 4 (+12M)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Tumor Response After Administration of NV1020 Followed by Chemotherapy, Determined by Radiological (Computed Tomography [CT] Scan) Assessment</measure>
    <time_frame>Screening (baseline), Chemo visit 1, Follow-up visits 1 (1 week post end of treatment), 2 (+6M), 3 (+9M), 4 (+12M)</time_frame>
    <description>Maximum percentage changes in tumor diameter after administration of NV1020 followed by chemotherapy as measured by CT scan and Modified Response Evaluation Criteria in Solid Tumors (RECIST) assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of NV1020: NV1020 Neutralizing Antibody Titer Assay</measure>
    <time_frame>Screening, Chemo Visit 1, Follow-up Visits 1 (1 week post end of treatment), 2 (+6M), 3 (+9M), 4 (+12M)</time_frame>
    <description>Mean change from baseline in NV1020 neutralizing antibody titer by dose cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression; Survival Time</measure>
    <time_frame>Progression: Chemo visit 1, FU1 (1 week post treatment), FU2 (+6M), FU3 (+9M), FU4 (+12M); Survival: death of patient</time_frame>
    <description>Progression assessed from CT and PET measurements and is determined as an increase of greater than or equal to 25% in the sum of the products of perpendicular diameters of all tumors, or the appearance of any new lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of NV1020: Serum Cytokines (INF Gamma)</measure>
    <time_frame>Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7)</time_frame>
    <description>Median change from baseline of Interferon (INF) gamma 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of NV1020: Serum Cytokines (IL-6)</measure>
    <time_frame>Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7)</time_frame>
    <description>Median change from baseline of Interleukin-6 (IL-6) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha)</measure>
    <time_frame>Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7)</time_frame>
    <description>Median change from baseline of tumor necrosis factor (TNF-alpha) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Safety and antitumor effects of NV1020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: Four escalating dose cohorts of NV1020 3x10^6 pfu, 1x10^7 pfu, 3x10^7 pfu, and 1x10^8 pfu administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.
Stage 2: Expansion of one dose cohort from Stage 1 of optimal NV1020 dose administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NV1020</intervention_name>
    <description>NV1020 dose levels: 3x10^6, 1x10^7, 3x10^7, and 1x10^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks</description>
    <arm_group_label>Safety and antitumor effects of NV1020</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and willingness to sign a written informed consent (includes
             willingness to avoid physical intimacy during and for 2 weeks post NV1020 treatment)

          2. 18 years or more of age

          3. Colorectal adenocarcinoma histologically confirmed within one year prior to enrollment
             in the study

          4. Liver dominant metastases (CT-measurable lesions with less than 50% total liver
             involvement), histologically confirmed

          5. Failed conventional chemotherapy for metastatic disease (e.g. tumors no longer
             responding to 5-FU/leucovorin in combination with irinotecan or oxaliplatin with or
             without one monoclonal antibody)

          6. Candidate for additional chemotherapy (and/or experimental anti-cancer therapy, if
             this is the only remaining treatment option)

          7. Karnofsky Performance Status 70% or greater

          8. Life expectancy greater than or equal to 4 months, based on the investigator's opinion

          9. Seropositive for herpes simplex virus-1 (HSV-1)

         10. Fecund females: negative for pregnancy test (urine or serum)

         11. Effective double-barrier contraception for a minimum of 2 months following final
             infusion of NV1020

        Exclusion Criteria:

          1. Dominant extrahepatic disease, including cerebral metastases, significant malignant
             ascites or other extrahepatic metastases that are symptomatic, in critical locations
             or otherwise likely to confound NV1020 evaluations, in the opinion of the investigator

          2. Seronegative for HSV-1

          3. Significant active/unstable non-malignant disease or laboratory test (hematology and
             chemistry) results that meet any of the following:

               -  White blood cell count (WBC) less than or equal to 3 x 10e3/mm3

               -  Absolute neutrophil count (ANC) less than or equal to 1.5 x 10e3/mm3

               -  Platelets less than or equal to 100,000/mm3

               -  Hemoglobin (Hgb) less than or equal to 9.0 g/dL

               -  Prothrombin time/partial thromboplastin time (PT/PTT) &gt; upper limit of normal
                  (ULN)

               -  Serum creatinine &gt; 2.0 mg/dL

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2.5 times
                  ULN or total bilirubin &gt; 1.5 times ULN

               -  Alkaline phosphatase &gt; 2.5 times ULN

          4. Chemotherapy &lt; 4 weeks prior to the first NV1020 infusion (mitomycin or nitrosurea &lt; 6
             weeks)

          5. Immunotherapy &lt; 6 weeks prior to the first NV1020 infusion

          6. Radiotherapy (external or internal) to the liver

          7. Major surgery (excluding pump placement and cholecystectomy) â‰¤ 2 weeks prior to the
             first NV1020 infusion but the subject must be clinically stable. Pump placement and
             cholecystectomy â‰¤ 1 week prior to the first NV1020 infusion but the subject must be
             clinically stable

          8. Female who is pregnant or nursing

          9. Patients wishing to conceive within 2 months after the last infusion of NV1020

         10. Any investigational agent administered less than or equal to 4 weeks prior to NV1020
             infusion

         11. Acute HSV infection requiring systemic antiviral therapy or history of serious HSV
             infection (e.g., ocular, encephalitic, etc.)

         12. Active viral hepatitis (evidence for infection with hepatitis A, B or C viruses)

         13. Known infection with HIV

         14. Known hypersensitivity to any component of the NV1020 formulation

         15. History of, or current, bleeding or coagulation disorder

         16. History of significant hepatic fibrosis, cirrhosis, or hemachromatosis

         17. History of malignancy other than colorectal cancer, within 5 years prior to start of
             study participation, with the exception of in situ cervical or skin carcinoma

         18. Active severe infection and any other concurrent disease or medical conditions that
             are likely to interfere with the study, as judged by the investigator

         19. Systemic corticosteroid administration &lt; 4 weeks prior to starting NV1020 treatment

         20. Prior treatment with NV1020 or other putative oncolytic viruses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hoda Tawfik, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MediGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <results_first_submitted>December 29, 2015</results_first_submitted>
  <results_first_submitted_qc>March 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2018</results_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer metastases to liver</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Colorectal Carcinoma</keyword>
  <keyword>Colorectal Tumors</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Rectum Cancer</keyword>
  <keyword>Rectum tumors</keyword>
  <keyword>Rectum carcinoma</keyword>
  <keyword>Colon cancer</keyword>
  <keyword>Colon tumors</keyword>
  <keyword>Colon carcinoma</keyword>
  <keyword>Rectum Neoplasms</keyword>
  <keyword>Colon Neoplasms</keyword>
  <keyword>Liver Neoplasms</keyword>
  <keyword>Hepatic Neoplasms</keyword>
  <keyword>Liver Tumors</keyword>
  <keyword>Liver cancer</keyword>
  <keyword>Hepatic Cancer</keyword>
  <keyword>Hepatic tumors</keyword>
  <keyword>metastatic to the liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NV1020</title>
          <description>Escalating doses of NV1020: 3x10^6, 1x10^7, 3x10^7, 1x10^8</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed NV1020 Therapy</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed NV1020 and Chemotherapy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other treatment</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NV1020</title>
          <description>Escalating doses of NV1020: 3x10^6, 1x10^7, 3x10^7, 1x10^8</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carcinoembryonic Antigen (CEA) Level at Screening</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175.5" spread="517.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Chemotherapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status (KPS)</title>
          <description>The KPS was rated as follows:
100 - Normal, no complaints, no evidence of disease; 90 - Able to carry on normal activity; minor signs or symptoms of disease; 80 - Normal activity with effort; some signs or symptoms of disease</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>KPS 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KPS 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KPS 80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events and Dose Limiting Adverse Events</title>
        <description>Incidence of adverse events for all patients (N=32); Overall incidence â‰¥20%; Adverse events listed by Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term</description>
        <time_frame>From start of treatment through 12 months after completion of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients in study</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events and Dose Limiting Adverse Events</title>
          <description>Incidence of adverse events for all patients (N=32); Overall incidence â‰¥20%; Adverse events listed by Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose limiting adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain upper</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema peripheral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Serum Carcinoembryonic Antigen (CEA) After Administration of NV1020 and 2 Cycles of Chemotherapy</title>
        <time_frame>Screening (baseline), Chemo visit 1, Chemo visit 2, Follow-up Visit 1 (1 week after end of treatment), Follow-up Visit 2 (+6M), Follow-up Visit 3 (+9M), Follow-up Visit 4 (+12M)</time_frame>
        <population>Number of participants analyzed decreases through the follow-up visits. Thus the &quot;Number of Participants Analyzed&quot; indicated here refer to the number at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Cohort 1</title>
            <description>NV1020 Dose 3x10^6 pfu (Stage 1)</description>
          </group>
          <group group_id="O2">
            <title>Dose Cohort 2</title>
            <description>NV1020 Dose 1x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O3">
            <title>Dose Cohort 3</title>
            <description>NV1020 Dose 3x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O4">
            <title>Dose Cohort 4</title>
            <description>NV1020 Dose 1x10^8 pfu (Stages 1 and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Serum Carcinoembryonic Antigen (CEA) After Administration of NV1020 and 2 Cycles of Chemotherapy</title>
          <population>Number of participants analyzed decreases through the follow-up visits. Thus the &quot;Number of Participants Analyzed&quot; indicated here refer to the number at baseline.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Baseline CEA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1814.4" spread="3105.2"/>
                    <measurement group_id="O2" value="161.0" spread="235.1"/>
                    <measurement group_id="O3" value="121.6" spread="230.3"/>
                    <measurement group_id="O4" value="181.7" spread="373.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Chemo visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="869.6" spread="1489.9"/>
                    <measurement group_id="O2" value="96.0" spread="106.1"/>
                    <measurement group_id="O3" value="8.6" spread="17.0"/>
                    <measurement group_id="O4" value="165.6" spread="410.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Chemo visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="13.2"/>
                    <measurement group_id="O2" value="194.4" spread="212.8"/>
                    <measurement group_id="O3" value="-0.6">N=1 for this timepoint</measurement>
                    <measurement group_id="O4" value="98.2" spread="254.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Follow-up 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-353.9" spread="628.8"/>
                    <measurement group_id="O2" value="615.6" spread="867.5"/>
                    <measurement group_id="O3" value="5.4" spread="5.8"/>
                    <measurement group_id="O4" value="97.0" spread="334.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Follow-up 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6995.9" spread="12110.6"/>
                    <measurement group_id="O2" value="134.7">N=1 for this timepoint</measurement>
                    <measurement group_id="O3" value="1.8" spread="3.5"/>
                    <measurement group_id="O4" value="97.3" spread="311.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Follow-up 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">N=0 for this timepoint</measurement>
                    <measurement group_id="O2" value="NA">N=0 for this timepoint</measurement>
                    <measurement group_id="O3" value="16.5">N=1 for this timepoint</measurement>
                    <measurement group_id="O4" value="-52.3" spread="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Follow-up 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">N=0 for this timepoint</measurement>
                    <measurement group_id="O2" value="NA">N=0 for this timepoint</measurement>
                    <measurement group_id="O3" value="-1.7">N=1 for this timepoint</measurement>
                    <measurement group_id="O4" value="290.9" spread="447.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Tumor Response After Administration of NV1020 Followed by Chemotherapy, Determined by Radiological (Computed Tomography [CT] Scan) Assessment</title>
        <description>Maximum percentage changes in tumor diameter after administration of NV1020 followed by chemotherapy as measured by CT scan and Modified Response Evaluation Criteria in Solid Tumors (RECIST) assessment</description>
        <time_frame>Screening (baseline), Chemo visit 1, Follow-up visits 1 (1 week post end of treatment), 2 (+6M), 3 (+9M), 4 (+12M)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1</title>
            <description>Escalating doses of NV1020: 3x10^6 pfu, 1x10^7 pfu, 3x10^7 pfu, 1x10^8 pfu</description>
          </group>
          <group group_id="O2">
            <title>Stage 2</title>
            <description>Optimal dose from Stage 1: 1x10^8 pfu</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Tumor Response After Administration of NV1020 Followed by Chemotherapy, Determined by Radiological (Computed Tomography [CT] Scan) Assessment</title>
          <description>Maximum percentage changes in tumor diameter after administration of NV1020 followed by chemotherapy as measured by CT scan and Modified Response Evaluation Criteria in Solid Tumors (RECIST) assessment</description>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient 101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.70"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.76"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.85"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 201</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.91"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 202</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.55"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 203</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 301</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 302</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.55"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 303</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.74"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 304</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 401</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.51"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 402</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.36"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.98"/>
                    <measurement group_id="O2" value="NA">This patient not in Stage 2 of study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 801</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 802</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="35.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 803</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="-35.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 804</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 805</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 806</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="18.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 807</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="29.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 808</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="16.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 809</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="30.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 810</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="57.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 811</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="-1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 812</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="-19.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 813</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="25.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 814</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="114.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 815</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 816</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="12.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 817</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 818</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="-11.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 819</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This patient not in Stage 1 of study</measurement>
                    <measurement group_id="O2" value="-24.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Effects of NV1020: NV1020 Neutralizing Antibody Titer Assay</title>
        <description>Mean change from baseline in NV1020 neutralizing antibody titer by dose cohort</description>
        <time_frame>Screening, Chemo Visit 1, Follow-up Visits 1 (1 week post end of treatment), 2 (+6M), 3 (+9M), 4 (+12M)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Cohort 1</title>
            <description>NV1020 Dose 3x10^6 pfu (Stage 1)</description>
          </group>
          <group group_id="O2">
            <title>Dose Cohort 2</title>
            <description>NV1020 Dose 1x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O3">
            <title>Dose Cohort 3</title>
            <description>NV1020 Dose 3x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O4">
            <title>Dose Cohort 4</title>
            <description>NV1020 Dose 1x10^8 pfu (Stages 1 and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Effects of NV1020: NV1020 Neutralizing Antibody Titer Assay</title>
          <description>Mean change from baseline in NV1020 neutralizing antibody titer by dose cohort</description>
          <units>antibody titer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Baseline Neutralizing Antibody</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282.7" spread="96.4"/>
                    <measurement group_id="O2" value="1242.7" spread="1585.2"/>
                    <measurement group_id="O3" value="1006.6" spread="844.6"/>
                    <measurement group_id="O4" value="334.2" spread="309.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Chemotherapy Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1341" spread="914"/>
                    <measurement group_id="O2" value="1061" spread="1430"/>
                    <measurement group_id="O3" value="4926" spread="1444"/>
                    <measurement group_id="O4" value="3481" spread="2251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Follow-up Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1231" spread="1382"/>
                    <measurement group_id="O2" value="950" spread="1344"/>
                    <measurement group_id="O3" value="2154" spread="473"/>
                    <measurement group_id="O4" value="2389" spread="1736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Follow-up Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="824" spread="622"/>
                    <measurement group_id="O2" value="1152">N=1 for this timepoint</measurement>
                    <measurement group_id="O3" value="1887" spread="1133"/>
                    <measurement group_id="O4" value="1292" spread="1245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Follow-up Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">N=0 for this timepoint</measurement>
                    <measurement group_id="O2" value="NA">N=0 for this timepoint</measurement>
                    <measurement group_id="O3" value="450">N=1 for this timepoint</measurement>
                    <measurement group_id="O4" value="1029" spread="863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change - Follow-up Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">N=0 for this timepoint</measurement>
                    <measurement group_id="O2" value="NA">N=0 for this timepoint</measurement>
                    <measurement group_id="O3" value="-543.1">N=1 for this timepoint</measurement>
                    <measurement group_id="O4" value="403" spread="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression; Survival Time</title>
        <description>Progression assessed from CT and PET measurements and is determined as an increase of greater than or equal to 25% in the sum of the products of perpendicular diameters of all tumors, or the appearance of any new lesion.</description>
        <time_frame>Progression: Chemo visit 1, FU1 (1 week post treatment), FU2 (+6M), FU3 (+9M), FU4 (+12M); Survival: death of patient</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1</title>
            <description>Escalating doses of NV1020: 3x10^6 pfu, 1x10^7 pfu, 3x10^7 pfu, 1x10^8 pfu</description>
          </group>
          <group group_id="O2">
            <title>Stage 2</title>
            <description>Optimal dose from Stage 1: 1x10^8 pfu</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression; Survival Time</title>
          <description>Progression assessed from CT and PET measurements and is determined as an increase of greater than or equal to 25% in the sum of the products of perpendicular diameters of all tumors, or the appearance of any new lesion.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median time to progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.8" upper_limit="6.9"/>
                    <measurement group_id="O2" value="6.4" lower_limit="2" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median survival time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="9.6" upper_limit="15.0"/>
                    <measurement group_id="O2" value="11.6" lower_limit="8.3" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>NV1020 Pharmacokinetics - Presence of NV1020 in Body Fluids/Skin</title>
        <description>Number of patients with NV1020 detected in saliva, skin, and/or mucosal surfaces; Analysis by polymerase chain reaction (PCR)</description>
        <time_frame>Daily for 2 weeks after the first and last NV1020 infusions</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients in study</description>
          </group>
        </group_list>
        <measure>
          <title>NV1020 Pharmacokinetics - Presence of NV1020 in Body Fluids/Skin</title>
          <description>Number of patients with NV1020 detected in saliva, skin, and/or mucosal surfaces; Analysis by polymerase chain reaction (PCR)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Safety - Hematology</title>
        <description>Number of patients with clinically significant hematology laboratory abnormalities by NV1020 dose cohort (Post baseline)</description>
        <time_frame>Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Cohort 1</title>
            <description>NV1020 Dose 3x10^6 pfu (Stage 1)</description>
          </group>
          <group group_id="O2">
            <title>Dose Cohort 2</title>
            <description>NV1020 Dose: 1x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O3">
            <title>Dose Cohort 3</title>
            <description>NV1020 Dose 3x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O4">
            <title>Dose Cohort 4</title>
            <description>NV1020 Dose 1x10^8 pfu (Stages 1 and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Safety - Hematology</title>
          <description>Number of patients with clinically significant hematology laboratory abnormalities by NV1020 dose cohort (Post baseline)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absolute neutrophil count (x10^3/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (g/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (bands) (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (segs) (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (x10^3/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells (x10^6/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells (x10^3/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Safety - Chemistry</title>
        <description>Number of patients with post-baseline clinically significant laboratory chemistry abnormalities by NV1020 dose cohort</description>
        <time_frame>Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Cohort 1</title>
            <description>NV1020 Dose 3x10^6 pfu (Stage 1)</description>
          </group>
          <group group_id="O2">
            <title>Dose Cohort 2</title>
            <description>NV1020 Dose 1x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O3">
            <title>Dose Cohort 3</title>
            <description>NV1020 Dose 3x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O4">
            <title>Dose Cohort 4</title>
            <description>NV1020 Dose 1x10^8 pfu (Stages 1 and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Safety - Chemistry</title>
          <description>Number of patients with post-baseline clinically significant laboratory chemistry abnormalities by NV1020 dose cohort</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline Phosphatase (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (SGPT) (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (SGOT) (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YGT/GGT (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Safety - Coagulation</title>
        <description>Number of patients with post-baseline clinically significant laboratory coagulation abnormalities by NV1020 dose cohort</description>
        <time_frame>Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Cohort 1</title>
            <description>NV1020 Dose 3x10^6 pfu (Stage 1)</description>
          </group>
          <group group_id="O2">
            <title>Dose Cohort 2</title>
            <description>NV1020 Dose 1x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O3">
            <title>Dose Cohort 3</title>
            <description>NV1020 Dose 3x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O4">
            <title>Dose Cohort 4</title>
            <description>NV1020 Dose 1x10^8 pfu (Stages 1 and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Safety - Coagulation</title>
          <description>Number of patients with post-baseline clinically significant laboratory coagulation abnormalities by NV1020 dose cohort</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-reactive Protein (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer (ug/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen (ug/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin Time (PT) (sec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Thromboplastin Time (PTT) (sec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Effects of NV1020: Serum Cytokines (INF Gamma)</title>
        <description>Median change from baseline of Interferon (INF) gamma 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)</description>
        <time_frame>Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Cohort 1</title>
            <description>NV1020 Dose 3x10^6 pfu (Stage 1)</description>
          </group>
          <group group_id="O2">
            <title>Dose Cohort 2</title>
            <description>NV1020 Dose 1x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O3">
            <title>Dose Cohort 3</title>
            <description>NV1020 Dose 3x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O4">
            <title>Dose Cohort 4</title>
            <description>NV1020 Dose 1x10^8 pfu (Stages 1 and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Effects of NV1020: Serum Cytokines (INF Gamma)</title>
          <description>Median change from baseline of Interferon (INF) gamma 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median Baseline INF gamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.6" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.6" upper_limit="1.7"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.6" upper_limit="1.3"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.6" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Change - Visit 1 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="0.1" upper_limit="6.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-1.1" upper_limit="0.5"/>
                    <measurement group_id="O3" value="4.7" lower_limit="3.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="22.9" lower_limit="0.0" upper_limit="169.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Change - Visit 3 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="2.9" upper_limit="42.1"/>
                    <measurement group_id="O2" value="0.8" lower_limit="-1.1" upper_limit="6.3"/>
                    <measurement group_id="O3" value="36.0" lower_limit="15.9" upper_limit="111.4"/>
                    <measurement group_id="O4" value="51.8" lower_limit="0.2" upper_limit="433.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Change - Visit 5 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.5" upper_limit="3.5"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.8" upper_limit="4.0"/>
                    <measurement group_id="O3" value="10.3" lower_limit="9.7" upper_limit="64.4"/>
                    <measurement group_id="O4" value="18.8" lower_limit="1.3" upper_limit="281.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Change - Visit 7 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.3" upper_limit="3.3"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-1.1" upper_limit="3.9"/>
                    <measurement group_id="O3" value="7.6" lower_limit="4.3" upper_limit="13.0"/>
                    <measurement group_id="O4" value="18.1" lower_limit="1.4" upper_limit="327.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Effects of NV1020: Serum Cytokines (IL-6)</title>
        <description>Median change from baseline of Interleukin-6 (IL-6) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)</description>
        <time_frame>Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Cohort 1</title>
            <description>NV1020 Dose 3x10^6 pfu (Stage 1)</description>
          </group>
          <group group_id="O2">
            <title>Dose Cohort 2</title>
            <description>NV1020 Dose 1x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O3">
            <title>Dose Cohort 3</title>
            <description>NV1020 Dose 3x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O4">
            <title>Dose Cohort 4</title>
            <description>NV1020 Dose 1x10^8 pfu (Stages 1 and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Effects of NV1020: Serum Cytokines (IL-6)</title>
          <description>Median change from baseline of Interleukin-6 (IL-6) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median Baseline IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4.2" upper_limit="8.3"/>
                    <measurement group_id="O2" value="11.0" lower_limit="6.5" upper_limit="12.0"/>
                    <measurement group_id="O3" value="15.5" lower_limit="3.7" upper_limit="31.0"/>
                    <measurement group_id="O4" value="6.2" lower_limit="1.6" upper_limit="169.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change - Visit 1 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="-4.8" upper_limit="27.8"/>
                    <measurement group_id="O2" value="6.0" lower_limit="0.0" upper_limit="19.0"/>
                    <measurement group_id="O3" value="16.5" lower_limit="3.8" upper_limit="57.0"/>
                    <measurement group_id="O4" value="32.1" lower_limit="-0.4" upper_limit="497.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change - Visit 3 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" lower_limit="16.1" upper_limit="194.7"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.0" upper_limit="13.5"/>
                    <measurement group_id="O3" value="50.2" lower_limit="34.0" upper_limit="475.0"/>
                    <measurement group_id="O4" value="60.6" lower_limit="1.7" upper_limit="989.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change - Visit 5 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="8.8" upper_limit="26.7"/>
                    <measurement group_id="O2" value="14.5" lower_limit="8.0" upper_limit="49.0"/>
                    <measurement group_id="O3" value="63.0" lower_limit="17.3" upper_limit="102.0"/>
                    <measurement group_id="O4" value="32.2" lower_limit="2.4" upper_limit="371.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change - Visit 7 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" lower_limit="19.1" upper_limit="44.8"/>
                    <measurement group_id="O2" value="8.5" lower_limit="8.0" upper_limit="49.0"/>
                    <measurement group_id="O3" value="11.3" lower_limit="10.0" upper_limit="62.0"/>
                    <measurement group_id="O4" value="43.0" lower_limit="8.0" upper_limit="433.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha)</title>
        <description>Median change from baseline of tumor necrosis factor (TNF-alpha) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)</description>
        <time_frame>Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Cohort 1</title>
            <description>NV1020 Dose 3x10^6 pfu (Stage 1)</description>
          </group>
          <group group_id="O2">
            <title>Dose Cohort 2</title>
            <description>NV1020 Dose 1x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O3">
            <title>Dose Cohort 3</title>
            <description>NV1020 Dose 3x10^7 pfu (Stage 1)</description>
          </group>
          <group group_id="O4">
            <title>Dose Cohort 4</title>
            <description>NV1020 Dose 1x10^8 pfu (Stages 1 and 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha)</title>
          <description>Median change from baseline of tumor necrosis factor (TNF-alpha) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median Baseline TNF-alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.6" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.6" upper_limit="2.2"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.8" upper_limit="4.9"/>
                    <measurement group_id="O4" value="1.3" lower_limit="0.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change - Visit 1 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-8.0" upper_limit="3.8"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="4.1"/>
                    <measurement group_id="O3" value="-0.2" lower_limit="-2.5" upper_limit="0.6"/>
                    <measurement group_id="O4" value="2.4" lower_limit="-0.9" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change - Visit 3 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.2" upper_limit="7.1"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.0" upper_limit="1.5"/>
                    <measurement group_id="O3" value="2.3" lower_limit="1.3" upper_limit="3.9"/>
                    <measurement group_id="O4" value="5.9" lower_limit="0.3" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change - Visit 5 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.0" upper_limit="3.3"/>
                    <measurement group_id="O2" value="1.3" lower_limit="-0.7" upper_limit="1.4"/>
                    <measurement group_id="O3" value="1.8" lower_limit="1.1" upper_limit="2.2"/>
                    <measurement group_id="O4" value="5.5" lower_limit="0.9" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change - Visit 7 (post 8 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.9" upper_limit="2.7"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-0.8" upper_limit="2.4"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.7" upper_limit="5.4"/>
                    <measurement group_id="O4" value="5.7" lower_limit="1.4" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years, 11 months (First subject enrolled to last subject completed)</time_frame>
      <desc>*Serious adverse events exclude those which were deemed to be unrelated to NV1020</desc>
      <group_list>
        <group group_id="E1">
          <title>NV1020</title>
          <description>Escalating doses of NV1020: 3x10^6, 1x10^7, 3x10^7, 1x10^8</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neurtopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="50" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="14" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="30" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdonimal tenderness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="111" subjects_affected="30" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="41" subjects_affected="18" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="36" subjects_affected="18" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaenemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director Regulatory Affairs</name_or_title>
      <organization>Medigene</organization>
      <phone>858-586-2252</phone>
      <email>p.larson@medigeneusa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

